Evidence map›Paper›PMID 24675986›Full record

ArticlePLoS pathogens2014

Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome.

Nazzarena Labo, Wendell Miley, Vickie Marshall, William Gillette, Dominic Esposito, Matthew Bess, Alexandra Turano, Thomas Uldrick, Mark N Polizzotto, Kathleen M Wyvill and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 86 citations in OpenAlex.

  1. Trial
  2. Article
  3. Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. LANA-specific CD4Nature communications · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Nazzarena LaboViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Wendell MileyViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Vickie MarshallViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
William GilletteProtein Expression Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Dominic EspositoProtein Expression Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Matthew BessProtein Expression Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Alexandra TuranoProtein Expression Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Thomas UldrickHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, United States of America.
Mark N PolizzottoHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, United States of America.
Kathleen M WyvillHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, United States of America.
Rachel BagniProtein Expression Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Robert YarchoanHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, United States of America.
Denise WhitbyViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USProtein Express (United States) · USJohns Hopkins University · US

Funding

Study of Tumor Pathogenesis and Development of Therapies for AIDS MalignanciesZIABC010885 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$15.7M
Pathogenesis and therapy of KSHV-associated MalignanciesZIABC011500 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POLIZZOTTO, MARK · 2013 to 2015
$669k
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

The Kaposi sarcoma associated herpesvirus (KSHV) genome encodes more than 85 open reading frames (ORFs). Serological evaluation of KSHV infection now generally relies on reactivity to just one latent and/or one lytic protein (commonly ORF73 and K8.1). Most of the other polypeptides encoded by the virus have unknown antigenic profiles. We have systematically expressed and purified products from 72 KSHV ORFs in recombinant systems and analyzed seroreactivity in US patients with KSHV-associated malignancies, and US blood donors (low KSHV seroprevalence population). We identified several KSHV proteins (ORF38, ORF61, ORF59 and K5) that elicited significant responses in individuals with KSHV-associated diseases. In these patients, patterns of reactivity were heterogeneous; however, HIV infection appeared to be associated with breadth and intensity of serological responses. Improved antigenic characterization of additional ORFs may increase the sensitivity of serologic assays, lead to more rapid progresses in understanding immune responses to KSHV, and allow for better comprehension of the natural history of KSHV infection. To this end, we have developed a bead-based multiplex assay detecting antibodies to six KSHV antigens.

Indexed as

Immunologic TechniquesAdultAgedAntibodies, ViralAntigens, ViralCoinfectionEnzyme-Linked Immunosorbent AssayFemaleHerpesviridae InfectionsHerpesvirus 8, HumanHIV InfectionsHumansMaleMiddle AgedOpen Reading FramesProteomeAntibodies, ViralAntigens, ViralProteome

Identifiers

PMID24675986
PMCPMC3968157
OpenAlexW1994077961

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.